Gilead Sciences (NASDAQ:GILD) Shares Unloaded Rep. Val T. Hoyle

Representative Val T. Hoyle (D-Oregon) recently sold shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Gilead Sciences stock on September 23rd. The trade occurred in the Representative’s “FIDELITY ROLLOVER IRA” account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marriott International (NASDAQ:MAR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of H&R Block (NYSE:HRB) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of NIKE (NYSE:NKE) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Bank of New York Mellon (NYSE:BK) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Cisco Systems (NASDAQ:CSCO) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Pentair (NYSE:PNR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Heico (NYSE:HEI.A) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Target (NYSE:TGT) on 9/23/2025.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $117.18 on Friday. The business’s 50-day moving average price is $114.65 and its two-hundred day moving average price is $110.26. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The company has a market capitalization of $145.40 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the previous year, the company posted $2.01 earnings per share. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares of the company’s stock, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $9,402,130. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GILD shares. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research note on Wednesday. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Citigroup lifted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.08.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences in the 1st quarter worth $25,000. Activest Wealth Management raised its holdings in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. GoalVest Advisory LLC raised its holdings in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new position in Gilead Sciences in the 2nd quarter worth $27,000. Finally, Goodman Advisory Group LLC bought a new position in Gilead Sciences in the 1st quarter worth $29,000. Institutional investors own 83.67% of the company’s stock.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon’s 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon’s 4th Congressional District. She declared candidacy for the 2026 election.

Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.